The interlacing anticancer effect of pharmacologic ascorbate, chloroquine, and resveratrol

Currently, a diagnosis with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) means a death warrant, so finding efficient therapeutic options is a pressing issue. Here, we presented that pharmacologic ascorbate, chloroquine and resveratrol co-treatment exerted a synergistic cytotoxic effect on PDAC cell lines. The observed synergistic cytotoxicity was a general feature in all investigated Cancer cell lines independent of the KRAS mutational status and seems to be independent of the Autophagy inhibitory effect of chloroquine. Furthermore, it seems that Apoptosis and Necroptosis are also not likely to play any role in the cytotoxicity of chloroquine. Both pharmacologic ascorbate and resveratrol caused double-strand DNA breaks accompanied by cell cycle arrest. It seems resveratrol-induced cytotoxicity is independent of Reactive Oxygen Species (ROS) generation and accompanied by a significant elevation of Caspase-3/7 activity, while pharmacologic ascorbate-induced cytotoxicity shows strong ROS dependence but proved to be caspase-independent. Our results are particularly important since ascorbate and resveratrol are natural compounds without significant harmful effects on normal cells, and chloroquine is a known antimalarial drug that can easily be repurposed.

KRAS; cancer cell death; chloroquine; combined cancer therapy; drug repurposing; pharmacologic ascorbate; resveratrol.